Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary FDA Releases gammaCore®, the First Non-Invasive Vagus Nerve Stimulation Therapy Applied at the Neck for Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients
First U.S. Food and Drug Administration (FDA) release for electroCore, a neuroscience and technology company  - Hand-held, non-invasive, easy-to-use device provides new option for the approximately 400,000 Americans living with this rare but extremely debilitating headache disorder  Basking Ridge,
Toggle Summary Mount Sinai Beth Israel Receive Award from The United States Department of Defense to Study Gulf War Illness with electroCore’s non-invasive vagus nerve stimulation therapy
The Pain & Fatigue Study Center at Mount Sinai Beth Israel in New York has been awarded a United States Army Medical Research grant to conduct a study into the treatment of veterans of the 1990-1991 Gulf War who have Gulf War Illness using electroCore’s non-invasive vagus nerve stimulation (nVNS)
Toggle Summary Presentation shows that healthcare costs for patients with a primary headache diagnosis cost four times more than a healthy patient due to comorbidities
Research presented at the Academy of Managed Care Pharmacy (AMCP) Nexus in early October in Washington, DC, showed that 60 percent of adult patients who were diagnosed with primary headache had one or more comorbidities which raised the average annual cost of their healthcare to over $20,000.
Toggle Summary Reorganization of electroCore management team as Frank Amato becomes CEO and founder JP Errico becomes Chief Science and Strategy Officer.
Basking Ridge, New Jersey: Frank Amato, previously Chief Operating Officer, has been appointed Chief Executive Officer of electroCore, the Merck-backed world leader in non-invasive vagus nerve stimulation (nVNS) therapy. This change is part of a management-proposed development plan, unanimously
Toggle Summary ElectroCore’s non-invasive vagus nerve stimulation (nVNS) demonstrates efficacy in preventing cluster headache and menstrual migraine
The results of two studies, presented at the American Headache Society (AHS) Science Meeting last weekend in San Diego, show that using electroCore’s non-invasive vagus nerve stimulation (nVNS) therapy, gammaCore®, is effective at preventing both cluster headache and menstrual migraine.
Toggle Summary Seven presentations on electroCore’s treatment for cluster headache and migraine will feature at American Headache Society science meeting.
Recent clinical and preclinical results using electroCore’s non-invasive vagus nerve stimulation (nVNS, gammaCore®) therapy in the treatment and prevention of primary headache are the subject of seven presentations at the American Headache Society (AHS) Science Meeting being held at San Diego next
Toggle Summary GammaCore is both effective and cost effective for the treatment of cluster headache
BASKING RIDGE, N.J: A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life.
Toggle Summary National Institute of Health Research (NIHR) publication reinforces potential role of gammaCore in helping UK patients manage medically unexplained symptoms (MUS)
electroCore welcomes the recent NIHR technology alert on gammaCore, which profiles the CE-marked device’s role in helping patients in the UK manage long-term neurological conditions such as migraine and medically unexplained symptoms. The alert, which is designed to notify clinicians and those
Toggle Summary NICE provides positive guidance on electroCore’s gammaCore treatment for the prevention and acute treatment of migraine and cluster headache.
BASKING RIDGE, N.J: The UK’s National Institute of Health and Care Excellence (NICE) has published guidance that electroCore’s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention and acute treatment of migraine and cluster headache is safe and can now be used in the NHS. 
Toggle Summary University of Bonn study shows that non-invasive vagus nerve stimulation (nVNS) device reduces number of migraine attacks and their intensity
A study published in the Journal of Headache and Pain, carried out by Dr. Thomas Kinfe of the University of Bonn, found that twice daily stimulation of the vagus nerve with the hand-held gammaCore nVNS device reduced the number of headache days per month from 14.7 to 8.9 (p